Clinical Trial Update: Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating TQB2450 in combination with Anlotinib capsule and chemotherapy for immunoresistant advanced non-small cell lung cancer. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: RECRUITING